Comparisons of causes of death and mortality rates among HIV-infected persons - Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras

被引:358
作者
Crum, NF
Riffenburgh, RH
Wegner, S
Agan, BK
Tasker, SA
Spooner, KM
Armstrong, AW
Fraser, S
Wallace, MR
机构
[1] USN, Med Ctr, Dept Clin Invest, San Diego, CA 92134 USA
[2] Triservice AIDS Clin Consortium, Rockville, MD USA
[3] US Mil Acad, HIV Res Program, Rockville, MD USA
[4] Wilford Hall USAF Med Ctr, Lackland AFB, TX 78236 USA
[5] Natl Naval Med Ctr, Bethesda, MD USA
[6] Walter Reed Army Med Ctr, Washington, DC 20307 USA
[7] USN, Med Ctr, Portsmouth, VA USA
[8] Tripler Army Med Ctr, Honolulu, HI 96859 USA
关键词
HIV; AIDS; mortality; survival; cause of death;
D O I
10.1097/01.qai.0000179459.31562.16
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Methods: Comparisons of death-related variables during the 3 eras were performed. Results: The number of deaths declined over the study period, with 987 deaths in the pre-HAART era, 159 deaths in the early HAART era (1997-1999), and 78 deaths in the late HAART era (2000-2003) (P < 0.01). The annual death rate peaked in 1995 (10.3 per 100 patients) and then declined to < 2 deaths per 100 persons in the late HAART era (P < 0.01). The proportion of deaths attributable to infection decreased, but infection remained the leading cause of death in our cohort, followed by cancer. Of those who died, there was an increasing proportion of non-HIV-related deaths (32% vs. 9%; P < 0.01), including cardiac disease (22% vs. 8%; P < 0.01) and trauma (8% vs. 2%; P = 0.01) in the post-HAART versus pre-HAART era. Despite the absence of intravenous drug use and the low prevalence of hepatitis C coinfection in our cohort, an increasing proportion of deaths in the HAART era were attributable to liver disease, although the numbers are small. Conclusions: Despite increasing concerns regarding antiretroviral resistance, the death rate among HIV-infected persons in our cohort continues to decline. Our data show a lower death rate than that reported among many other US HIV-infected populations; this may be the result of open access to health care. A shift in the causes of death toward non-HIV-related causes suggests that a more comprehensive health care approach may be needed for optimal life expectancy; this may include enhanced screening for malignancy and heart disease as well as preventive measures for liver disease and accidents.
引用
收藏
页码:194 / 200
页数:7
相关论文
共 35 条
[1]  
[Anonymous], 1992, MMWR-MORBID MORTAL W, V41, P1
[2]   Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection [J].
Bica, I ;
McGovern, B ;
Dhar, R ;
Stone, D ;
McGowan, K ;
Scheib, R ;
Snydman, DR .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (03) :492-497
[3]   Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy [J].
Bonnet, F ;
Lewden, C ;
May, T ;
Heripret, L ;
Jougla, E ;
Bevilacqua, S ;
Costagliola, D ;
Salmon, D ;
Chêne, G ;
Morlat, P .
CANCER, 2004, 101 (02) :317-324
[4]   Declining HIV/AIDS mortality in New York City [J].
Chiasson, MA ;
Berenson, L ;
Li, WH ;
Schwartz, S ;
Singh, T ;
Forlenza, S ;
Mojica, BA ;
Hamburg, MA .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (01) :59-64
[5]   Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy [J].
Cohen, MH ;
French, AL ;
Benning, L ;
Kovacs, A ;
Anastos, K ;
Young, M ;
Minkoff, H ;
Hessol, NA .
AMERICAN JOURNAL OF MEDICINE, 2002, 113 (02) :91-98
[6]   Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration [J].
Detels, R ;
Muñoz, A ;
McFarlane, G ;
Kingsley, LA ;
Margolick, JB ;
Giorgi, J ;
Scharager, LD ;
Phair, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (17) :1497-1503
[7]  
FOLCH EH, 2002, 9 C RETR OPP INF SEA
[8]  
Fordyce EJ, 2002, J ACQ IMMUN DEF SYND, V30, P111, DOI 10.1097/00042560-200205010-00015
[9]   Mortality among drug users in the AIDS era [J].
Goedert, JJ ;
Pizza, G ;
Gritti, FM ;
Costigiola, P ;
Boschini, A ;
Bini, A ;
Lazzari, C ;
Palareti, A .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1995, 24 (06) :1204-1210
[10]  
Grulich AE, 1999, J ACQ IMMUN DEF SYND, V21, pS27